UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 2) 1

Merrimack Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, \$0.01 par value
(Title of Class of Securities)
590328209
(CUSIP Number)
December 31, 2019
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
⊠ Rule 13d-1(c)
□ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the <i>Notes</i>).

1	NAME OF REPOR	TING PERSON	
	Biotechnolog	y Value Fund, L.P.	
2			(a) 🗵
			(b) □
			` /
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		0 shares	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0 shares		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	TING PERSON	
	PN		

1	NAME OF REPORTING PERSON		
	BVF I GP LI	LC	
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES		0022 1011101011210	
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH		SIMILED VOING FOWER	
REPORTING		0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
1210011 11111	,	SOLD BIST COTTIVE TO WERK	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		SIMINED DISTOSTIVE FOWER	
		0 shares	
9	ACCRECATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
3	AGGREGATE AIV.	COULT DEVELOCIATED ON NED DI EACH REPORTING LEGGON	
	0 shares		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
10	CHECK BOX II' I	THE AGGREGATE AMOUNT IN NOW (3) EXCEODES CERTAIN STIANES	
11	DEBCENT OF CI	ASS REPRESENTED BY AMOUNT IN ROW (9)	
11	I EKCENT OF CL.	AGG REI REGENTED DI AMIOUNI IN ROW (3)	
	0%		
12	TYPE OF REPORT	TINC DEDSON	
14	I I PE OF KEPOK	THE FERSON	
	00		
	1 00		

1	NAME OF REPORT	TING PERSON	
		Value Fund II, L.P.	
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
	020 002 01121		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	8	0 shares SHARED DISPOSITIVE POWER	
	O	SHARED DISPOSITIVE POWER	
		0 shares	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0 shares		
10		IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
			_
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	ING PERSON	
	PN		

			
1	NAME OF REPOR	TING PERSON	
	BVF II GP L		
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	D.L.		
NUMBER OF	Delaware 5	SOLE VOTING POWER	
SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH	0	SHAKED VOTINGTOWER	
REPORTING		0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		0 shares	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0 shares		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DED CENTE OF C	ACC DEDDECEMPED DV AMOUNT IN DOW (0)	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	TING PERSON	
12	TIL OF KEIOK	TITO I BROOM	
	00		

1	NAME OF REPOR	TING PERSON	
		gy Value Trading Fund OS LP	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠		
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Cayman Islai	nds	
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		0 shares	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0 shares		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	TING PERSON	
	PN		

	·		
1	NAME OF REPOR	TING PERSON	
	BVF Partners		
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Cayman Islaı	nds	
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		0 shares	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0 shares		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	TING PERSON	
	CO		

1	NAME OF REPO	RTING PERSON	
		OLDINGS LLC	
2	CHECK THE API	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHID OI	R PLACE OF ORGANIZATION	
4	CITIZENSIIIF OI	A FLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		STATES STOTES TO WER	
		0 shares	
9	AGGREGATE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0 shares		
10	CHECK BOX IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DEBCENT OF CI	ASS REPRESENTED BY AMOUNT IN ROW (9)	
11	I EKCENT OF CL	ADD RELIGIED DI AMOUNT IN ROW (3)	
	0%		
12	TYPE OF REPOR	TING PERSON	
	00		

1	NAME OF REPOR	TING PERSON	
	BVF Partners	s.L.P.	
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ✓		
			(b) □
			` ,
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		0.1	
0	A CODECATE AND	0 shares	
9	AGGKEGALE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0 shares		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П
10	CHECK BOA IF I	THE AGGREGATE AMOUNT IN KOW (3) EXCLUDES CERTAIN SHAKES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
11	LICENTI OF CER	io initialities bi initionii in itom (s)	
	0%		
12	TYPE OF REPORT	TING PERSON	
	PN, IA		

			
1	NAME OF REPOR	TING PERSON	
	BVF Inc.		
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Dala		
NILIM (DED OF	Delaware 5	COLE MOTING DOMED	
NUMBER OF SHARES	5	SOLE VOTING POWER	
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH	U	SHAKED VOTING POWER	
REPORTING		0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
1210011 (1111	,	SOLE BIST COTTIVE TO WER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		0 shares	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0 shares		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%	WYG PEDGOV	
12	TYPE OF REPORT	TING PERSON	
	60		
	CO		

	·		
1	NAME OF REPOR	TING PERSON	
	Mark N. Lam		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ⊠		
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	United States		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		0 shares	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		0 shares	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0 shares		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	0%		
12	TYPE OF REPORT	TING PERSON	
	IN		

Item 1(a). Name of Issuer:

Merrimack Pharmaceuticals, Inc., a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

One Broadway, 14th Floor Cambridge, Massachusetts 02142

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF I GP LLC ("BVF GP") 44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF II GP LLC ("BVF2 GP")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF Inc.

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common Stock, \$0.01 par value (the "Shares")

Item 2(e). CUSIP Number:

590328209

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment company registered under Section 8 of the Investment Company Act.
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	//	A church plan that is excluded from the definition of an investment company under Section $3(c)(14)$ of the Investment Company Act.
(j)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k)	//	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership.

As of December 31, 2019, the Reporting Persons no longer beneficially owned any Shares of the Issuer.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or

Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2020

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF II GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark Lampert President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark Lampert

Chief Executive Officer

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF INC.

By: /s/ Mark N. Lampert

Mark Lampert President

/s/ Mark N. Lampert

MARK N. LAMPERT

15

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the shares of Common Stock of Merrimack Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated: February 14, 2020

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF II GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark Lampert President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark Lampert

Chief Executive Officer

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF INC.

By: /s/ Mark N. Lampert

Mark Lampert President

/s/ Mark N. Lampert

MARK N. LAMPERT